Clinical Guideline Alerts Banner Image
FDA Drug Approvals Banner Image
  • Leqembi (Eisai)
    • For the treatment of Alzheimer’s disease (AD).
  • Airsupra (AstraZeneca)
    • As-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.
  • Rybelsus (Novo Nordisk)
    • First-line treatment option for adults with type 2 diabetes who have not previously taken a diabetes treatment.
  • Rykindo (Luye Pharma)
    • For the treatment of schizophrenia in adults and as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.
  • Adacel (Sanofi)
    • For use during the third trimester of pregnancy to help protect against pertussis, or whooping cough, in infants younger than two months of age.
  • Tukysa (Janssen)
    • In combination with trastuzumab for use in RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy.
  • Brukinsa (BeiGene)
    • For chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Brenzavvy (TheracosBio)
    • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
  • Keytruda (Merck)
    • In the adjuvant setting for patients with stage IB-IIIA non–small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy.
  • Jaypirca (Eli Lilly)
    • For relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy.
  • Orserdu (Stemline Therapeutics)
    • For postmenopausal women or men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer that progressed on at least one line of endocrine therapy.

Copyright © 2023 Guideline Central, All rights reserved.